Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of the new finding that most PTC consist of a mixture of tumor cells with wild-type and mutant BRAF, we examined the associations between the percentage of BRAFV600E alleles and both the clinicopathological parameters at time of diagnosis and the disease outcome in a large series of PTCs. Study Design: Tumors from 168 patients with PTC were genotyped for BRAFV600E using BigDye Terminator sequencing and pyrosequencing, and the clinical parameters were analyzed. The associations between clinicopathological characteristics, including disease recurrence at follow-up (median 5.1 yr) and the percentage of mutant BRAF alleles were assessed. Results: The observed prevalence of BRAFV600E was higher when using pyrosequencing then when using BigDye Terminator sequencing (53.6 vs. 36.9%). In the PTC positive for BRAFV600E, the percentage of mutant alleles ranged from 5.1 to 44.7% of the total BRAF alleles, with a median of 20.6%. The presence or the percentage of BRAFV600E alleles did not correlate significantly with sex, multicentricity, lymph node metastasis, or tumor stage. The percentage of BRAFV600E alleles directly correlated with age at diagnosis and tumor volume (R2 = 0.223, P = 0.039, and R2 = 0.166, P < 0.001, respectively). The percentage of BRAF V600E alleles (P = 0.014), tumor volume (P = 0.012), and lymph node metastasis (P = 0.008) predicted the disease outcome. The odds ratio of recurrence for PTC with BRAFV600E alleles of 30% or greater, compared with that for PTC with BRAFV600E alleles of less than 30%, was 5.31 (P = 0.002). Conclusions: A high percentage of BRAFV600E alleles defines a PTC molecular subtype and predicts a poorer disease outcome. The analysis of BRAF mutations by pyrosequencing is useful to refine the risk stratification of patients with PTC. Copyright © 2012 by The Endocrine Society.
A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome / A. Guerra, L. Fugazzola, V. Marotta, M. Cirillo, S. Rossi, V. Cirello, I. Forno, T. Moccia, A. Budillon, M. Vitale. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - 97:7(2012 Jul), pp. 2333-2340.
|Titolo:||A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome|
FUGAZZOLA, LAURA (Secondo)
|Parole Chiave:||adolescent; adult; aged; aged, 80 and over; alleles; amino acid substitution; carcinoma; Cohort studies; DNA mutational analysis; disease-free survival; female; gene frequency; humans; male; middle aged; prognosis; proto-oncogene proteins B-raf; thyroid neoplasms; treatment outcome; tumor markers, biological; young adult; mutation, missense; biochemistry; clinical biochemistry; endocrinology; biochemistry (medical); endocrinology, diabetes and metabolism; medicine (all)|
|Settore Scientifico Disciplinare:||Settore MED/13 - Endocrinologia|
|Data di pubblicazione:||lug-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1210/jc.2011-3106|
|Appare nelle tipologie:||01 - Articolo su periodico|